<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226134</url>
  </required_header>
  <id_info>
    <org_study_id>965-Med/ERC-08</org_study_id>
    <nct_id>NCT01226134</nct_id>
  </id_info>
  <brief_title>Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia</brief_title>
  <acronym>EIGEAPFD</acronym>
  <official_title>Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pathogenesis of functional dyspepsia is poorly understood. Gastrointestinal motor&#xD;
      abnormalities, Helicobacter pylori infection, impaired gastric accommodation to a meal,&#xD;
      hypersensitivity of the afferent nerves of the gut, psychological disturbances and central&#xD;
      nervous system dysfunction have been proposed.&#xD;
&#xD;
      Pharmacological treatments for patients with functional dyspepsia remain unsatisfactory. Only&#xD;
      small benefits relative to placebo have been found with histamine H2 receptor antagonists,&#xD;
      proton pump inhibitor and Helicobacter pylori eradication.&#xD;
&#xD;
      Itopride is a dopamine antagonist with acetylcholinesterase inhibitory actions. This agent is&#xD;
      currently indicated for patients with various upper GI symptoms.&#xD;
&#xD;
      This study is aimed to evaluate the effect of Itopride on gastric emptying(by 13-C Octanoic&#xD;
      acid breath Test), accommodation (by Gastric Scintigraphy SPECT and slow nutrient drinking&#xD;
      test)and symptoms in FD patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      phase3 clinical trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of Itopride on Gastric Emptying,accommodation and capacity of tolerating a nutrient drink in patients with Functional Dyspepsia</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of Itopride on symptom improvement in patient with Functional Dyspepsia</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Gastric Emptying</condition>
  <condition>Gastric Accommodation</condition>
  <arm_group>
    <arm_group_label>1.Itopride Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Control placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive placebo tablets for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride,</intervention_name>
    <description>Itopride,50 mg capsules,thrice a day,for Four weeks</description>
    <arm_group_label>1.Itopride Group</arm_group_label>
    <other_name>Gananton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules,thrice a day for four weeks</description>
    <arm_group_label>2.Control placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All adult male or non-pregnant female patients who are diagnosed as functional&#xD;
             dyspepsia and fulfilling Rome III criteria (1) will be considered&#xD;
&#xD;
          2. Patients should be negative for H. pylori on gastric biopsy and Urea Breath Test.&#xD;
&#xD;
          3. duodenal biopsy in these patients should be negative for giardiasis or celiac disease&#xD;
             or any other established organic pathology&#xD;
&#xD;
          4. A normal upper abdominal ultrasound&#xD;
&#xD;
          5. Willing to participate and give consent for participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years&#xD;
&#xD;
          2. Helicobacter Pylori positive on gastric biopsy and / or UBT.&#xD;
&#xD;
          3. Taking other medications that alter gastric motility like macrolide&#xD;
&#xD;
               -  anti-emetics and antibiotics .&#xD;
&#xD;
          4. Pregnant or breast-feeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahab Abid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahab Abid, MD</last_name>
    <phone>+92 21 4864656</phone>
    <phone_ext>4656</phone_ext>
    <email>shahab.abid@aku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wasim Jafri, MD</last_name>
    <phone>+92 21 4864659</phone>
    <phone_ext>4659</phone_ext>
    <email>wasim.jafri@aku.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shahab Abid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wasim Jafri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maseeh Uzzaman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rakhshanda Bilal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soobia Siddiqui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greger Lindberg, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Shahab Abid</name_title>
    <organization>Aga Khan University,Karachi, Pakistan</organization>
  </responsible_party>
  <keyword>Functional Dyspepsia</keyword>
  <keyword>Itopride</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Gastric Accommodation</keyword>
  <keyword>Dyspeptic Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

